Efforts to strengthen vaccine safety are advancing through better reporting tools, targeted training, and improved monitoring of adverse events.

The safety of orphan drugs is hard to monitor as they target rare diseases afflicting small patient populations. However, an initiative led by the SFDA aims to improve this.

In 2018, the SFDA launched a strategic project for regional pharmacovigilance centres, to enhance activities among health institutions across the Kingdom of Saudi Arabia.